Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Galecto (NASDAQ: GLTO) granted inducement equity awards on March 2, 2026 to four newly hired, non-executive employees, approved by its independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

The awards are non-qualified stock options to purchase an aggregate of 153,700 shares at an exercise price of $29.58 per share, with a 10-year term and vesting of 25% after one year then monthly over 36 months.

Key Figures

Inducement options granted: 153,700 shares Exercise price: $29.58 per share Option term: 10 years +5 more

8 metrics

Inducement options granted 153,700 shares Aggregate non-qualified stock options granted March 2, 2026

Exercise price $29.58 per share Strike price for inducement stock options

Option term 10 years Duration of inducement stock options from grant date

Initial vesting 25% Portion vesting on first anniversary of grant date

Remainder vesting period 36 months Equal monthly vesting after first anniversary

Employees receiving grants 4 employees Newly hired, non-executive employees

Current share price $28.08 Price before publication, down 6.56% over 24h

52-week range $2.01 – $38.33 Low and high prior to this news

Market Reality Check

Price: $28.08 Vol: Volume 102,784 is about 7...

low vol

$28.08 Last Close

Volume Volume 102,784 is about 74% below the 20-day average of 391,312, indicating subdued trading relative to recent norms. low

Technical Shares at $28.08 are trading above the 200-day MA of $12.48, but sit 26.73% below the 52-week high of $38.33 after a large run from the $2.01 52-week low.

Peers on Argus

GLTO fell 6.56% while 3 Argus-tracked biotech peers (including TOVX, AZTR, DRMA)...

3 Down

GLTO fell 6.56% while 3 Argus-tracked biotech peers (including TOVX, AZTR, DRMA) also moved down, with median losses around 3.4%, indicating broader sector weakness alongside this company-specific HR announcement.

Historical Context

5 past events · Latest: Mar 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 02	Conference participation	Neutral	+1.6%	Announcement of participation in Leerink Partners 2026 Global Healthcare Conference.
Feb 12	Offering closing	Negative	-3.0%	Closing of $316.3M underwritten offering and full exercise of underwriters’ option.
Feb 10	Offering pricing	Negative	+1.3%	Pricing of $275M underwritten public offering of common shares at $19.00.
Feb 10	Offering announcement	Negative	+1.3%	Proposed underwritten offering of common and Series C non-voting preferred stock.
Jan 12	Strategic update	Positive	+6.4%	Outline of 2026 clinical milestones and runway supported by a $285M PIPE.

Pattern Detected

Recent financing and strategic updates have mostly seen price moves that align with the perceived tone: dilution-related offerings were followed by pressure, while strategic/clinical updates skewed positive.

Recent Company History

Over the past few months, Galecto has focused on capital raising and strategic repositioning. In January 2026, it highlighted 2026 milestones and runway into 2029, which coincided with a 6.44% gain. In February 2026, a sequence of underwritten offerings and preferred conversions funded its expanded hematology pipeline, with mixed short-term price reactions. A recent conference participation notice on March 2, 2026 saw a modest 1.59% rise. Today’s inducement option grants fit into this ongoing equity- and incentive-driven capital structure evolution.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-10

An automatic shelf registration on Form S-3ASR filed on February 10, 2026 is effective, allowing Galecto to issue common and preferred stock, debt securities, warrants and units via prospectus supplements. This shelf has already been used in at least 2 offerings (424B5 filings on February 10 and 11, 2026).

Market Pulse Summary

This announcement details inducement equity awards of 153,700 non-qualified stock options with a 10‑...

Analysis

This announcement details inducement equity awards of 153,700 non-qualified stock options with a 10‑year term and exercise price of $29.58, vesting over four years under the 2022 Inducement Plan. It follows a series of recent capital markets actions supported by an effective S-3ASR shelf and prior offerings. Investors may watch how future equity grants, additional shelf takedowns, and progress on the company’s hematology pipeline influence the balance between dilution and growth execution.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, stock option agreement

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"consist of non-qualified stock options to purchase an aggregate of 153,700"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

stock option agreement technical

"subject to the terms and conditions of a stock option agreement."

A stock option agreement is a formal contract that gives an individual the right to buy or sell a specific number of shares of a company's stock at a set price within a certain period. For investors, it’s an important tool because it can provide opportunities to profit from stock price movements or to protect against potential losses, making it a key element in financial planning and investment strategies.

AI-generated analysis. Not financial advice.

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted equity awards on March 2, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by Galecto’s independent Compensation Committee and were made as material inducements to such individuals’ acceptance of employment with Galecto in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 153,700 shares of the Galecto’s common stock with a 10-year term and an exercise price of $29.58 per share. The options vest as to 25% on the first anniversary of the applicable grant date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Galecto, Inc. Inducement Plan, and the terms and conditions of a stock option agreement.

About Galecto, Inc.

Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.

Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

FAQ

What inducement grants did Galecto (GLTO) announce on March 4, 2026?

Galecto granted non-qualified stock options totaling 153,700 shares as inducement awards to four new hires. According to Galecto, the options have a 10-year term, $29.58 exercise price, and standard time-based vesting starting after one year.

How do the Galecto (GLTO) inducement options vest and what is the exercise price?

The options vest 25% on the first anniversary, then monthly over the next 36 months. According to Galecto, the exercise price for the aggregate 153,700-share grant is $29.58 per share.

Why did Galecto (GLTO) use Nasdaq Listing Rule 5635(c)(4) for the March 2026 grants?

Galecto used Nasdaq Listing Rule 5635(c)(4) to classify the awards as material inducements for new employees. According to Galecto, the independent Compensation Committee approved the grants under that rule on March 2, 2026.

Who received the March 2, 2026 inducement grants from Galecto (GLTO)?

Four newly hired, non-executive employees received the inducement option awards. According to Galecto, these grants were made to induce acceptance of employment and were approved by the independent Compensation Committee.

What plan governs the terms of Galecto's (GLTO) March 2026 inducement option grants?

The inducement grants are governed by the 2022 Galecto Inducement Plan and individual stock option agreements. According to Galecto, the awards are subject to those plan terms and standard option agreement conditions.